Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

Sexual health

Volumn 2, Issue 3, 2005, Pages 153-163

  Nolan, David ^a   Mallal, Simon ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADIPOSE TISSUE; BODY COMPOSITION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; MALE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; STANDARD;

ADIPOSE TISSUE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PRIMARY PREVENTION; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 33644788620     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH04058     Document Type: Review

References (81)